A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
Conditions:   Advanced Solid Tumor;   Castration-Resistant Prostatic Cancer;   Malignant Melanoma;   Pancreatic Ductal Carcinoma;   Hepatocellular Cancer;   Epithelial Ovarian Cancer;   Renal Cell Carcinoma
Interventions:   Biological: MGC018;   Biological: lorigerlimab
Sponsor:   MacroGenics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 25, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments